Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer OSLO, Norway, June 18, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company...
Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases )
Also on site :